NAFPD exacerbation by hyperlipidemia combined with hyperuricemia: a pilot rat experiment in lipidomics

NAFPD exacerbation by hyperlipidemia combined with hyperuricemia: a pilot rat experiment in lipidomics

BackgroundHyperuricemia and non-alcoholic fatty pancreas disease (NAFPD) are prevalent metabolic diseases, but the relationship between them remains underexplored.MethodsEighteen Sprague–Dawley rats were randomly assigned to three groups: normal (CON), high-fat (PO), and high-fat high-uric acid (PH)...

Full description

Saved in:

Bibliographic Details
Main Authors:	Jingyun Li, Yongjian Chen, Shilin Li, Guorong Lyu, Furong Yan, Jiajing Guo, Jing Cheng, Yun Chen, Jiaojiao Lin, Yating Zeng
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-01-01
Series:	Frontiers in Nutrition
Subjects:	hyperuricemia lipidomics non-alcoholic fatty pancreas disease non-alcoholic fatty liver disease glycerophospholipids
Online Access:	https://www.frontiersin.org/articles/10.3389/fnut.2024.1437373/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Effects of PCSK9 inhibitors on metabolic-associated fatty liver disease: a short review
by: Ewelina Jakielska, et al.
Published: (2023-03-01)

Clinical and Pathogenetic Parallels of Nonalcoholic Fatty Liver Disease and Gallstone Disease
by: Aleksey O. Bueverov
Published: (2019-03-01)

Metabolic and Genetic Determinants of Lipid Metabolism Disruption in Non-Alcoholic Fatty Liver Disease
by: O. Yu. Kytikova, et al.
Published: (2020-05-01)

Transitioning from NAFLD to MAFLD and MASLD: the toxic relationship with alcohol consumption
by: Mubin Ozercan, et al.
Published: (2025-01-01)

Intrahepatic Cholestasis in Non-Alcoholic Fatty Liver Disease: Pathogenesis and Role of Ademetionine in Treatment
by: Ye. N. Shirokova
Published: (2023-08-01)

Improvement of non-alcoholic fatty liver disease treatment
by: P. I. Seliverstov, et al.
Published: (2014-10-01)

Risk of Cirrhosis in Patients with Non-alcoholic Fatty Liver Disease and Previous Viral Hepatitis B
by: S. N. Batskikh, et al.
Published: (2020-09-01)

Effects of Aramchol in patients with nonalcoholic fatty liver disease (NAFLD). A systematic review and meta-analysis
by: Adnan Malik, et al.
Published: (2022-02-01)

Practical Aspects of Clinical Manifestations, Pathogenesis and Therapy of Alcoholic Liver Disease and Non-alcoholic Fatty Liver Disease: Expert Opinion
by: V. V. Tsukanov, et al.
Published: (2023-11-01)

Epidemiologic features of non-alcoholic fatty liver disease in Russia
by: O. M. Drapkina, et al.
Published: (2014-10-01)

The Safety and Efficacy of Dietary Epigallocatechin Gallate Supplementation for the Management of Obesity and Non-Alcoholic Fatty Liver Disease: Recent Updates
by: Ruike Yan, et al.
Published: (2025-01-01)

Usefulness of pemafibrate for non-alcoholic fatty liver disease with hypertriglyceridemia
by: Masahiro Kikuchi, et al.
Published: (2024-09-01)

Patient Management in Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus
by: A. E. Bagriy, et al.
Published: (2021-06-01)

Can fecal calprotectin be used as a biomarker of non-alcoholic fatty liver disease in obese adolescents?
by: Büşra Tetik Dinçer, et al.
Published: (2024-12-01)

Non-alcoholic fatty liver disease in Poland: how and at what stage is diagnosed, and how is treated. A survey study
by: Irena Ciećko-Michalska, et al.
Published: (2019-09-01)

Detectability of Liver Steatosis and Fibrosis with Transient Elastography and Controlled Attenuation Parameter in Residents of St. Petersburg
by: V. P. Kovyazina, et al.
Published: (2021-04-01)

Dose-response relationship between the fatty liver index and asthma risk: NHANES 2001~2018
by: Tengfei Sun, et al.
Published: (2025-02-01)

Profile of Children With Non-alcoholic Fatty Liver Disease Referred to a Hospital in Iran
by: Amin Ghanbari, et al.
Published: (2024-12-01)

Lymph Node Adiposity and Metabolic Dysfunction-Associated Steatotic Liver Disease
by: Jessica M. Rubino, et al.
Published: (2025-01-01)

Association between Bioelectrical Impedance Parameters, Magnetic Resonance Imaging Muscle Parameters, and Fatty Liver Severity in Children and Adolescents
by: Kyungchul Song, et al.
Published: (2025-01-01)

Antioxidants in the Treatment of Chronic Diffuse Liver Diseases (the Results of the “MAXAR” Observational Program)
by: M. V. Mayevskaya, et al.
Published: (2018-11-01)

Association of alcohol abstinence with risk of hyperuricemia in rural Chinese adults: the Henan Rural Cohort Study
by: Xiaokang Dong, et al.
Published: (2025-02-01)

Gut microbiome in non-alcoholic fatty liver disease
by: Anastasios Mpountouridis, et al.
Published: (2025-01-01)

Perioperative treatment with cilostazol reverses steatosis and improves liver regeneration after major hepatectomy in a steatotic rat model
by: Sebastian Holländer, et al.
Published: (2025-01-01)

Methodical approaches in experimental modelling of non-alcoholic fatty liver disease
by: N. V. Bivalkevich, et al.
Published: (2015-09-01)

The Role of the Microbiome and Intestinal Mucosal Barrier in the Development and Progression of Non-Alcoholic Fatty Liver Disease
by: T. S. Krolevets, et al.
Published: (2020-12-01)

Human umbilical cord derived-mesenchymal stem cells alleviate lipid metabolism disturbances of hepatocytes via mitochondrial transport
by: Jing Xue, et al.
Published: (2025-01-01)

Polyphenols synergistic drugs to ameliorate non-alcoholic fatty liver disease via signal pathway and gut microbiota: A review
by: Hongcai Li, et al.
Published: (2025-02-01)

Effect of Ginkgolide B on Non-Alcoholic Fatty Liver Disease based on Notch Signaling Pathway
by: Hong YU, et al.
Published: (2021-04-01)

Association between non-alcoholic fatty liver disease and progression of abdominal aortic aneurysm: a multicenter study
by: Ximing Wang, et al.
Published: (2025-01-01)

Pathogenic role of lipids in non-alcoholic fatty liver disease
by: Yu. O. Shulpekova
Published: (2012-02-01)

Hepatoprotection by L-Ornithine L-Aspartate in Non-Alcoholic Fatty Liver Disease
by: Roger F. Butterworth, et al.
Published: (2019-03-01)

Global research trends in Chinese medicine for the treatment of non-alcoholic fatty liver disease (NAFLD): A bibliometric study
by: Kangjie li, et al.
Published: (2025-03-01)

The rationale for the aggressive progression of MASLD in patients with type 2 diabetes
by: Valeria Michelle Fernández-Garibay, et al.
Published: (2025-01-01)

Associations between Chinese Visceral Adiposity Index and the Risk of Metabolic Dysfunction-associated Steatotic Liver Disease and Liver Fibrosis: A Large Cross-sectional Study
by: Hui Liu, et al.
Published: (2025-01-01)

Mediterranean diet improves liver health but does not protect against azoxymethane-induced colon tumorigenesis compared to Western diet in A/J mice
by: Weimin Guo, et al.
Published: (2025-03-01)

Effects of Aerobic Exercise on Leukocyte-Mediated Liver Destruction in a Rat Model of Metabolic Syndrome
by: Fatmanur Er, et al.
Published: (2024-10-01)

Liver and Nutrition. An Optimal Diet for Non-Alcoholic Fatty Liver Disease
by: M. V. Mayevskaya, et al.
Published: (2018-11-01)

The gut-liver axis mechanism of increased susceptibility to non-alcoholic fatty disease in female offspring rats with prenatal caffeine exposure
by: Qian Wang, et al.
Published: (2024-11-01)

Higher intakes of lysine, threonine and valine are inversely associated with non-alcoholic fatty liver disease risk: A community-based case-control study in the Chinese elderly
by: Xueqi Li, et al.
Published: (2024-01-01)